LifeMD Offers New Oral GLP-1 Pill

LifeMD is enhancing its weight management program by offering Foundayo (orforglipron), an oral GLP-1 medication developed by Eli Lilly and Company. This new pill provides eligible patients with an alternative to injectable GLP-1 therapies, potentially improving adherence and convenience. The inclusion of Foundayo signifies LifeMD's dedication to expanding access to innovative treatments for weight management, catering to a growing demand for effective and user-friendly solutions in the healthcare market.